and Baht 100 million for construction projects. The captioned capital increase is expected to be completed on December 29, 2017. Construction Income In the 3rd quarter of 2017, the company and its

% decrease since there has been no any new awarded project and such an income has been gained from 9 projects on hand since 2016 and another 3 projects completed in 2017. The 2017income of Baht 72.04 million

recognized the revenue by completed segment but not yet completed which those reached the invoice. As a consequence, trade receivables decreased, resulting in an increase unbilled receivables. Unbilled

แบบแจ้งชื่อผู้บริหารของบริษัท “Fill in Form 35-E1 via the SEC electronic filing system only. Then, print out the completed form, affix the authorized signature and submit the hardcopy to the SEC

the securities clearing house or central securities depository to continue its business; (3) guidelines or procedures for business recovery; (4) guidelines or procedures for administration of assets and

Percentage Total Revenues 501.45 1,148.64 (647.19) (56.34) Cost of Goods Sold and Service (577.57) (1,085.84) (508.27) (46.81) Sell and Administration Expenses (22.54) (39.38) (16.85) (42.77) Net Profit (Loss

Revenues 643.92 1,150.40 (506.48) (44.03) Cost of Goods Sold and Service (671.54) (1,073.38) (401.83) (37.44) Sell and Administration Expenses (23.20) (28.87) (5.67) (19.63) Net Profit (Loss) (50.71) 47.00

quite a longer process of licenses than expected, e.g., import license and food serial number from the Food and Drug Administration (FDA). In addition, the Company is in the process of adjusting its

outsourced production with fully completed services, from formulation development, research, marketing and label design and packaging services, including cosmetic product filings with the Food and Drug

Manufacturer and supplier of cosmetic products by way of outsourced production with fully completed services, from formulation บริษัท ดีโอดี ไบโอเทค จ ำกัด (มหำชน) 111 หมู่ท่ี 2 ต ำบลท่ำจนี อ ำเภอเมืองสมุทรสำคร